What is Chembio Diagnostics?
Chembio Diagnostics, Inc., headquartered in Hauppauge, New York, is a developer, manufacturer, marketer, and licensor of rapid point-of-care (POC) diagnostic tests. The company specializes in detecting infectious diseases, offering a portfolio that includes rapid tests for HIV and syphilis. Their product line features lateral flow rapid HIV tests and the Dual Path Platform (DPP) HIV 1/2 Assay Test, known for their visually interpreted results. Chembio also provides a DPP HIV-Syphilis multiplex test and a Hepatitis-C detection test. These diagnostic solutions are marketed under established trademarks such as STAT-PAK, SURE CHECK, STAT VIEW, and DPP, as well as through private label partnerships. The company serves a diverse clientele including medical laboratories, hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments across the United States and internationally. Chembio has also engaged in strategic collaborations to develop POC diagnostic tests for traumatic brain injury and specific types of cancer, signaling a commitment to innovation beyond its core infectious disease offerings.
How much funding has Chembio Diagnostics raised?
Chembio Diagnostics has raised a total of $31M across 1 funding round:
Share Placement
$31M
Share Placement (2020): $31M, investors not publicly disclosed
What's next for Chembio Diagnostics?
The recent major strategic investment positions Chembio Diagnostics for accelerated growth and enhanced market penetration. This capital infusion is expected to fuel further research and development, potentially expanding the company's diagnostic test portfolio into new disease areas and strengthening its existing product lines. The company's focus on POC diagnostics aligns with the global trend towards decentralized healthcare, enabling faster and more accessible disease detection. Strategic partnerships and collaborations will likely remain a key component of Chembio's expansion strategy, allowing it to leverage external expertise and market access to drive innovation and commercial success in the competitive diagnostics landscape.
See full Chembio Diagnostics company page
